在临床中，放疗的应用场景非常广泛：对于早期肺癌、食管癌、宫颈癌等癌症，放疗可以达到与手术相 当的根治效果，尤其适合身体状况不适合手术的患者；对于中晚期癌症，放疗可以与手术、化疗等结合 使用，缩小肿瘤体积、缓解疼痛、控制病情进展，提升患者的生活质量，延长生存期；此外，对于一些 晚期转移性肿瘤，放疗还能起到姑息治疗的作用，减轻患者的症状，让患者在治疗期间更有尊严。 预防先行：主动预防+定期筛查，筑牢防癌第一道防线 从临床来看，很多癌症的发生都与不良生活习惯密切相关。比如长期吸烟、过量饮酒是肺癌、食管癌、 肝癌等多种癌症的重要诱因；高热量、高脂肪、低纤维的饮食结构，会增加结直肠癌、乳腺癌的发病风 险；缺乏运动、长期熬夜、精神压力过大，则会导致免疫力下降，为癌细胞的滋生提供"可乘之机"。 因此，养成戒烟限酒、均衡饮食、规律作息、适度运动的健康习惯，是预防癌症的基础。同时，定期进 行针对性的癌症筛查也至关重要，比如40岁以上人群定期做肺癌低剂量CT筛查，女性定期做乳腺癌、 宫颈癌筛查，结直肠癌高危人群定期做肠镜筛查等，能帮助我们更早发现潜在的病变，为治疗争取时 间。 精准放疗： 告别认知误区 它是抗癌重要利器 当不幸确 ...

Group 1 - The core viewpoint of the article highlights that Xi'an Deyi Group, a leading company in the domestic gamma knife market, is attempting to go public on the Hong Kong Stock Exchange after a four-year hiatus, despite facing significant financial challenges and market skepticism regarding its growth potential [1][2][3] - Deyi Group holds a dominant market share of 70% in the Chinese gamma knife market, but its revenue for 2023 and 2024 is projected to be lower than four years ago, with net losses increasing significantly [1][4] - The global market for radiation surgery is expected to grow from $92.4 billion in 2024 to $138.9 billion by 2030, with the Chinese market anticipated to increase from 594 million yuan to 1.058 billion yuan during the same period [3] Group 2 - Deyi Group's core product, CybeRay, is the first gamma radiation therapy device approved by both the Chinese National Medical Products Administration and the U.S. FDA, but the company struggles to convert its technological advancements into commercial success [3][6] - The company faces challenges in expanding its market presence, as the gamma knife is considered a niche product compared to linear accelerators, which dominate the radiation therapy market [4][5] - Financially, Deyi Group's revenue has not only stagnated but has also declined from 2020 to 2023, with losses increasing from 1.77 million yuan in 2020 to 69.78 million yuan in 2023 [6][7] Group 3 - The company has shown signs of cash reserve strain, with cash decreasing from 334 million yuan at the end of 2023 to 126 million yuan by the end of 2024, and further down to less than 60 million yuan by February 2025 [7][8] - Several early investors have opted to cash out, indicating a lack of confidence in the company's future, especially after the failed attempt to list on the A-share market [8][9] - The company has signed agreements that may trigger buyback obligations for its controlling shareholders if the IPO fails, adding pressure to its financial situation [9][10]